

This spreadsheet is updated monthly and enables self-audit of a medicines formulary for adherence to current NICE Technology Appraisals. All guidelines refer to adults unless indicated.

Technology appraisals 96  
 CCG/ICS commissioned 23  
 Non-CCG/ICS commissioned 46  
 Not applicable 28  
 CCG/ICS commissioned and approved 22 (96%)  
 Average days to compliance 40

Title	Recommendation	Published	Type	Implement	Commissioner	Local decision	Compliance	Notes	Local information
<a href="#">Daratumumab monotherapy for treating relapsed and refractory multiple myeloma [TA783]</a>	Recommended	13/04/2022	TA	12/07/2022	Non-CCG/ICS			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
<a href="#">Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer [TA784]</a>	Recommended	20/04/2022	TA	19/07/2022	Non-CCG/ICS			This technology is commissioned by NHS England. Providers are NHS hospitals trusts.	NHS England
<a href="#">Nivolumab with cabozantinib for untreated advanced renal cell carcinoma (terminated appraisal) [TA785]</a>	Terminated appraisal	20/04/2022	TA					N/A	Terminated Appraisal
<a href="#">Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies [TA786]</a>	Recommended	27/04/2022	TA	26/07/2022	Non-CCG/ICS			This technology is commissioned by NHS England. Providers are NHS hospitals trusts.	NHS England
<a href="#">Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable [TA787]</a>	Recommended	27/04/2022	TA	26/07/2022	Non-CCG/ICS			This technology is commissioned by NHS England. Providers are NHS hospitals trusts.	NHS England
<a href="#">Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy [TA788]</a>	Recommended	11/05/2022	TA	09/08/2022	Non-CCG/ICS			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
<a href="#">Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations [TA789]</a>	Recommended	18/05/2022	TA	16/08/2022	Non-CCG/ICS			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
<a href="#">TYRX Absorbable Antibacterial Envelope for preventing infection from cardiac implantable electronic devices (terminated appraisal) [TA790]</a>	Terminated appraisal	25/05/2022	TA					N/A	Terminated Appraisal
<a href="#">Romosozumab for treating severe osteoporosis [TA791]</a>	Recommended	25/05/2022	TA	23/08/2022	CCG/ICS	27/07/2022	63	This technology is commissioned by integrated care systems and clinical commissioning groups. Providers are NHS hospital trusts.	Red
<a href="#">Filgotinib for treating moderately to severely active ulcerative colitis [TA792]</a>	Recommended	01/06/2022	TA	30/08/2022	CCG/ICS	22/06/2022	21	This technology is commissioned by integrated care systems/clinical commissioning groups. Providers are NHS hospital trusts.	Red
<a href="#">Anifrolumab for treating active autoantibody-positive systemic lupus erythematosus (terminated appraisal) [TA793]</a>	Terminated appraisal	08/06/2022	TA					N/A	Terminated Appraisal

Title	Recommendation	Published	Type	Implement	Commissioner	Local decision	Compliance	Notes	Local information
<a href="#">Diroximel fumarate for treating relapsing–remitting multiple sclerosis[TA794]</a>	Recommended	08/06/2022	TA	06/09/2022	Non-CCG/ICS			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
<a href="#">Ibrutinib for treating Waldenstrom's macroglobulinaemia[TA795]</a>	Not recommended	08/06/2022	TA					N/A	Not recommended
<a href="#">Venetoclax for treating chronic lymphocytic leukaemia[TA796]</a>	Recommended	15/06/2022	TA	13/09/2022	Non-CCG/ICS			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
<a href="#">Enfortumab vedotin for previously treated locally advanced or metastatic urothelial cancer (terminated appraisal)[TA797]</a>	Terminated appraisal	15/06/2022	TA					N/A	Terminated Appraisal
<a href="#">Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation[TA798]</a>	Recommended	22/06/2022	TA	20/09/2022	Non-CCG/ICS			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
<a href="#">Faricimab for treating diabetic macular oedema[TA799]</a>	Recommended	29/06/2022	TA (Fast track)	29/07/2022	CCG/ICS	27/07/2022	28	This technology is commissioned by integrated care systems. Providers are NHS hospital trusts.	Red
<a href="#">Faricimab for treating wet age-related macular degeneration[TA800]</a>	Recommended	29/06/2022	TA (Fast track)	29/07/2022	CCG/ICS	27/07/2022	28	This technology is commissioned by integrated care systems. Providers are NHS hospital trusts.	Red
<a href="#">Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer[TA801]</a>	Recommended	29/06/2022	TA	27/09/2022	Non-CCG/ICS			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
<a href="#">Cemiplimab for treating advanced cutaneous squamous cell carcinoma[TA802]</a>	Recommended	29/06/2022	TA	27/09/2022	Non-CCG/ICS			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
<a href="#">Teduglutide for treating short bowel syndrome[TA804]</a>	Recommended	30/06/2022	TA	28/09/2022	Non-CCG/ICS			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
<a href="#">Fenfluramine for treating seizures associated with Dravet syndrome[TA808]</a>	Recommended	08/07/2022	TA	06/10/2022	Non-CCG/ICS			This technology is commissioned by NHS England. Providers are tertiary care providers and NHS hospital trusts.	NHS England
<a href="#">Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs[TA803]</a>	Recommended	13/07/2022	TA (Fast track)	12/08/2022	CCG/ICS	27/07/2022	14	Risankizumab is commissioned by integrated care systems and clinical commissioning groups. Providers are NHS hospital trusts.	Red
<a href="#">Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides[TA805]</a>	Recommended	13/07/2022	TA	11/10/2022	CCG/ICS	28/09/2022	77	This technology is commissioned by integrated care systems. Providers are primary care and NHS hospital trusts.	Green

Title	Recommendation	Published	Type	Implement	Commissioner	Local decision	Compliance	Notes	Local information
<a href="#">Belimumab for treating lupus nephritis (terminated appraisal)[TA806]</a>	Terminated appraisal	13/07/2022	TA					N/A	Terminated Appraisal
<a href="#">Roxadustat for treating symptomatic anaemia in chronic kidney disease[TA807]</a>	Recommended	13/07/2022	TA	11/10/2022	CCG/ICS	28/09/2022	77	This technology is commissioned by integrated care systems. Providers are NHS hospital trusts.	Red
<a href="#">Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease[TA809]</a>	Recommended	20/07/2022	TA	18/10/2022	Non-CCG/ICS			Imlifidase is commissioned by NHS England. Providers are specialist kidney transplant units within NHS hospital trusts.	NHS England
<a href="#">Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence[TA810]</a>	Recommended	20/07/2022	TA	18/10/2022	Non-CCG/ICS			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
<a href="#">Duvelisib for treating relapsed or refractory chronic lymphocytic leukaemia after 2 or more treatments (terminated appraisal)[TA811]</a>	Terminated appraisal	27/07/2022	TA					N/A	Terminated Appraisal
<a href="#">Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer[TA812]</a>	Not recommended	03/08/2022	TA					N/A	Not recommended
<a href="#">Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors[TA813]</a>	Recommended	03/08/2022	TA	01/11/2022	Non-CCG/ICS			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
<a href="#">Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis[TA814]</a>	Recommended	03/08/2022	TA (EAMS)	02/09/2022	CCG/ICS	28/09/2022	56	These technologies for adults are commissioned by integrated care systems and clinical commissioning groups, the technologies for adolescents are commissioned by NHS England. Providers are NHS hospitals trusts.	Red
<a href="#">Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs[TA815]</a>	Recommended	10/08/2022	TA	08/11/2022	CCG/ICS	28/09/2022	49	This technology is commissioned by integrated care systems. Providers are NHS hospital trusts.	Red
<a href="#">Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer[TA816]</a>	Recommended	10/08/2022	TA	08/11/2022	Non-CCG/ICS			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
<a href="#">Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence[TA817]</a>	Recommended	10/08/2022	TA	08/11/2022	Non-CCG/ICS			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
<a href="#">Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma[TA818]</a>	Recommended	17/08/2022	TA	15/11/2022	Non-CCG/ICS			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England

Title	Recommendation	Published	Type	Implement	Commissioner	Local decision	Compliance	Notes	Local information
<a href="#">Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapies[TA819]</a>	Recommended	17/08/2022	TA	15/11/2022	Non-CCG/ICS			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
<a href="#">Avalglucosidase alfa for treating Pompe disease[TA821]</a>	Recommended	24/08/2022	TA	22/11/2022	Non-CCG/ICS			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
<a href="#">Brolocizumab for treating diabetic macular oedema[TA820]</a>	Recommended	31/08/2022	TA (Fast track)	30/09/2022	CCG/ICS	28/09/2022	28	This technology is commissioned by integrated care systems. Providers are NHS hospital trusts.	Red
<a href="#">Melphalan for haematological diseases before allogeneic haematopoietic stem cell transplant (terminated appraisal)[TA822]</a>	Terminated appraisal	14/09/2022	TA					N/A	Terminated Appraisal
<a href="#">Dexamethasone intravitreal implant for treating diabetic macular oedema[TA824]</a>	Recommended	14/09/2022	TA	13/12/2022	CCG/ICS	26/10/2022	42	This technology is commissioned by integrated care systems. Providers are NHS hospital trusts.	Red
<a href="#">Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis[TA825]</a>	Recommended	21/09/2022	TA	20/12/2022	Non-CCG/ICS			This technology is commissioned by NHS England. Providers are specialist centres with expertise in the management of ANCA-associated vasculitis.	NHS England
<a href="#">Vedolizumab for treating chronic refractory pouchitis after surgery for ulcerative colitis (terminated appraisal)[TA826]</a>	Not recommended	21/09/2022	TA					N/A	Terminated Appraisal
<a href="#">Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer[TA823]</a>	Recommended	28/09/2022	TA	27/12/2022	Non-CCG/ICS			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
<a href="#">Upadacitinib for treating active ankylosing spondylitis[TA829]</a>	Recommended	30/09/2022	TA (Fast track)	30/10/2022	CCG/ICS	26/10/2022	26	This technology is commissioned by integrated care systems. Providers are NHS hospital trusts.	Red
<a href="#">Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy[TA327]</a>	Recommended	05/10/2022	TA	03/01/2023	Non-CCG/ICS			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
<a href="#">Ozanimod for treating moderately to severely active ulcerative colitis[TA828]</a>	Recommended	05/10/2022	TA	03/01/2023	CCG/ICS	26/10/2022	21	This technology is commissioned by integrated care systems. Providers are NHS hospital trusts.	Red
<a href="#">Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer[TA831]</a>	Not recommended	05/10/2022	TA					N/A	Not recommended
<a href="#">SQ HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (terminated appraisal)[TA834]</a>	Terminated appraisal	12/10/2022	TA					N/A	Terminated Appraisal

Title	Recommendation	Published	Type	Implement	Commissioner	Local decision	Compliance	Notes	Local information
<a href="#">Pembrolizumab for adjuvant treatment of renal cell carcinoma[TA830]</a>	Recommended	19/10/2022	TA	17/01/2023	Non-CCG/ICS			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
<a href="#">Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroids[TA832]</a>	Recommended	19/10/2022	TA	17/01/2023	CCG/ICS	23/11/2022	35	This technology is commissioned by integrated care systems. Providers are NHS hospital trusts and primary care providers.	Amber initiated
<a href="#">Zanubrutinib for treating Waldenstrom's macroglobulinaemia[TA833]</a>	Recommended	19/10/2022	TA	17/01/2023	Non-CCG/ICS			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
<a href="#">Fostamatinib for treating refractory chronic immune thrombocytopenia[TA835]</a>	Recommended	19/10/2022	TA	17/01/2023	CCG/ICS	23/11/2022	35	This technology is commissioned by integrated care systems. Providers are NHS hospital trusts.	Red
<a href="#">Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy[TA836]</a>	Recommended	26/10/2022	TA	24/01/2023	Non-CCG/ICS			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
<a href="#">Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma[TA837]</a>	Recommended	26/10/2022	TA	24/01/2023	Non-CCG/ICS			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
<a href="#">Slow-release potassium bicarbonate–potassium citrate for treating distal renal tubular acidosis (terminated appraisal)[TA838]</a>	Terminated appraisal	02/11/2022	TA					N/A	Terminated Appraisal
<a href="#">Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids (terminated appraisal)[TA839]</a>	Terminated appraisal	16/11/2022	TA					N/A	Terminated Appraisal
<a href="#">Ruxolitinib for treating chronic graft versus host disease refractory to corticosteroids (terminated appraisal)[TA840]</a>	Terminated appraisal	16/11/2022	TA					N/A	Terminated Appraisal
<a href="#">Carfilzomib with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)[TA841]</a>	Terminated appraisal	22/11/2022	TA					N/A	Terminated Appraisal
<a href="#">Tisagenlecleucel for treating follicular lymphoma after 2 or more therapies (terminated appraisal)[TA842]</a>	Terminated appraisal	22/11/2022	TA					N/A	Terminated Appraisal
<a href="#">Luspatercept for treating anaemia caused by beta-thalassaemia (terminated appraisal)[TA843]</a>	Terminated appraisal	24/11/2022	TA					N/A	Terminated Appraisal
<a href="#">Luspatercept for treating anaemia caused by myelodysplastic syndromes (terminated appraisal)[TA844]</a>	Terminated appraisal	24/11/2022	TA					N/A	Terminated Appraisal

Title	Recommendation	Published	Type	Implement	Commissioner	Local decision	Compliance	Notes	Local information
<a href="#">Mepolizumab for treating eosinophilic granulomatosis with polyangiitis (terminated appraisal)[TA845]</a>	Terminated appraisal	29/11/2022	TA					N/A	Terminated Appraisal
<a href="#">Mepolizumab for treating severe hypereosinophilic syndrome (terminated appraisal)[TA846]</a>	Terminated appraisal	29/11/2022	TA					N/A	Terminated Appraisal
<a href="#">Mepolizumab for treating severe chronic rhinosinusitis with nasal polyps (terminated appraisal)[TA847]</a>	Terminated appraisal	29/11/2022	TA					N/A	Terminated Appraisal
<a href="#">Cemiplimab for untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer (terminated appraisal) [TA848]</a>	Terminated appraisal	01/12/2022	TA					N/A	Terminated Appraisal
<a href="#">Cabozantinib for previously treated advanced hepatocellular carcinoma [TA849]</a>	Recommended	14/12/2022	TA	14/03/2023	Non-CCG/ICS			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
<a href="#">Amivantamab for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy [TA850]</a>	Not recommended	14/12/2022	TA					N/A	Not recommended
<a href="#">Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer [TA851]</a>	Recommended	14/12/2022	TA	14/03/2023	Non-CCG/ICS			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
<a href="#">Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more treatments [TA852]</a>	Recommended	14/12/2022	TA	14/03/2023	Non-CCG/ICS			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
<a href="#">Esketamine nasal spray for treatment-resistant depression [TA854]</a>	Not recommended	14/12/2022	TA					N/A	Black
<a href="#">Avatrombopag for treating primary chronic immune thrombocytopenia [TA853]</a>	Recommended	15/12/2022	TA	15/03/2023	CCG/ICS	25/01/2023	41	This technology is commissioned by integrated care systems. Providers are NHS hospital trusts.	Red
<a href="#">Mococertinib for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy [TA855]</a>	Recommended	04/01/2023	TA	04/04/2023	Non-CCG/ICS			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
<a href="#">Upadacitinib for treating moderately to severely active ulcerative colitis [TA856]</a>	Recommended	04/01/2023	TA	04/04/2023	CCG/ICS	22/02/2023	49	This technology is commissioned by integrated care systems. Providers are NHS hospital trusts.	Red
<a href="#">Nivolumab with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma [TA857]</a>	Recommended	11/01/2023	TA	11/04/2023	Non-CCG/ICS			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
<a href="#">Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma [TA858]</a>	Recommended	11/01/2023	TA	11/04/2023	Non-CCG/ICS			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England

Title	Recommendation	Published	Type	Implement	Commissioner	Local decision	Compliance	Notes	Local information
<a href="#">Angiotensin II for treating vasodilator-resistant hypotension caused by septic or distributive shock (terminated appraisal) [TA859]</a>	Terminated appraisal	16/01/2023	TA					N/A	Terminated Appraisal
<a href="#">Maribavir for treating refractory cytomegalovirus infection after transplant [TA860]</a>	Recommended	18/01/2023	TA	18/04/2023	Non-CCG/ICS			Maribavir is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
<a href="#">Upadacitinib for treating active non-radiographic axial spondyloarthritis [TA861]</a>	Recommended	01/02/2023	TA (Cost comparison)	03/03/2023	CCG/ICS	22/02/2023	21	This technology is commissioned by integrated care systems. Providers are NHS hospital trusts.	Red
<a href="#">Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments [TA862]</a>	Recommended	01/02/2023	TA	02/05/2023	Non-CCG/ICS			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
<a href="#">Somatrogon for treating growth disturbance in children and young people aged 3 years and over [TA863]</a>	Recommended	01/02/2023	TA (Cost comparison)	03/03/2023	CCG/ICS	22/02/2023	21	This technology is commissioned by integrated care boards. Providers are NHS hospital trusts.	Red
<a href="#">Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted [TA864]</a>	Recommended	01/02/2023	TA	02/05/2023	Non-CCG/ICS			This technology is commissioned by NHS England. Providers are Specialist Respiratory Centres.	NHS England
<a href="#">Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma [TA865]</a>	Recommended	08/02/2023	TA	09/05/2023	Non-CCG/ICS			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
<a href="#">Regorafenib for previously treated metastatic colorectal cancer [TA866]</a>	Recommended	08/02/2023	TA	09/05/2023	Non-CCG/ICS			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
<a href="#">Vutrisiran for treating hereditary transthyretin-related amyloidosis [TA868]</a>	Recommended	15/02/2023	TA	16/05/2023	Non-CCG/ICS			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
<a href="#">Mitapivat for treating pyruvate kinase deficiency (terminated appraisal) [TA867]</a>	Terminated appraisal	16/02/2023	TA					N/A	Terminated Appraisal
<a href="#">Teclistamab for treating relapsed or refractory multiple myeloma after 3 or more therapies (terminated appraisal) [TA869]</a>	Terminated appraisal	16/02/2023	TA					N/A	Terminated Appraisal
<a href="#">Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma [TA870]</a>	Recommended	22/02/2023	TA	23/05/2023	Non-CCG/ICS			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
<a href="#">Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies [TA872]</a>	Recommended	28/02/2023	TA	29/05/2023	Non-CCG/ICS			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
<a href="#">Eptinezumab for preventing migraine [TA871]</a>	Recommended	01/03/2023	TA (Cost comparison)	31/03/2023	CCG/ICS	22/03/2023	21	Eptinezumab is commissioned by integrated care boards. Providers are NHS hospital trusts.	Red
<a href="#">Cannabidiol for treating seizures caused by tuberous sclerosis complex [TA873]</a>	Recommended	01/03/2023	TA	30/05/2023	Non-CCG/ICS			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England
<a href="#">Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma [TA874]</a>	Recommended	01/03/2023	TA	30/05/2023	Non-CCG/ICS			This technology is commissioned by hospital trusts . NHS England . Providers are NHS hospital trusts.	NHS England
<a href="#">Semaqlutide for managing overweight and obesity [TA875]</a>	Recommended	08/03/2023	TA	TBC	CCG/ICS			This technology is commissioned by Integrated care systems. Providers are NHS hospital trusts and primary care.	TBC. Product is not yet launched and commercially available in the UK
<a href="#">Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer [TA876]</a>	Recommended	22/03/2023	TA	20/06/2023	Non-CCG/ICS			This technology is commissioned by NHS England. Providers are NHS hospital trusts.	NHS England

Title	Recommendation	Published	Type	Implement	Commissioner	Local decision	Compliance	Notes	Local information
<a href="#">Finerenone for treating chronic kidney disease in type 2 diabetes [TA877]</a>	Recommended	23/03/2023	TA	21/06/2023	CCG/ICS	03/05/2023	41	This technology is commissioned by integrated care boards. Providers are primary care services, NHS hospital trusts and tertiary care services.	Amber initiated
<a href="#">Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 [TA878]</a>	Partially recommended	29/03/2023	TA	27/06/2023	CCG/ICS	27/06/2023	90	These technologies are commissioned by integrated care boards (ICB's). Providers are NHS Hospital trusts and primary care.	Red statement (nirmatrelvir plus ritonavir, sotrovimab and tocilizumab) and black statement (casirivimab plus imdevimab)